Summary:
A randomized, double-blind, double-dummy, active controlled study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of abbv-3373 in subjects with moderate to severe rheumatoid arthritis.
Qualified Participants Must:
• Attend all study visits
• Be diagnosed with rheumatoid arthritis
• Adult male or female
• Between 18 and 75 years of age inclusive at screening
• Be biologic naive
• Incomplete response to methotrexate of 15mg to 25mg and stable for 3 months prior to first dose
Qualified Participants May Receive:
Study treatment at no cost, doctors visit at no cost, blood work results at no cost, receive $40.00 per visit once patient has been qualified and enrolled into the study.